DDDC Personal Webpage
 
   

蹕 傖

Cheng Luo, Ph.D.
Associate Professor

Tel:? +86-21-50806600 ext 1308
+86-21-50271399

Email: cluo@mail.shcnc.ac.cn
﹛ ﹛

EDUCATIONAL BACKGROUND﹛

Feb 2008-＃ Associate Professor of Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Acadamy of Sciences
2005-2008 Postdoctoral fellow in Marmorstein＊s Lab, The Wistar Institute & Dept of Chem., University of Pennsylvania
2004-2005 Assistant Professor of Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Acadamy of Sciences
2001-2004 Ph.D. Candidate of Organic Chemistry, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Acadamy of Sciences
1998- 2001 Dept of Chem., Fudan University, Major in Theoretical Chem., M.S.
1990- 1994 Dept.of Chem., Fuzhou University, B.S.

   
   
   
﹛ ﹛

RESEARCH FOCUS

﹛

 1.Computer Aided Drug Design (virtual screening, 3D-QSAR, Fragment-based drug design and SBDD);
2.Protein structural modeling, molecular dynamics simulation, QM-MM calculation, and free energy prediction;
3.Biochemical and biophysical research tools centered around X-ray crystal structure determination;
 

RECENT PUBLICATIONS

  1. Nitai C. Hait, Jeremy Allegood, Michael Maceyka, Graham M. Strub, Kuzhuvelil B. Harikumar, Sandeep K. Singh, Cheng Luo, Ronen Marmorstein, Tomasz Kordula, Sheldon Milstien, Sarah Spiegel, Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate, Science, in press.
  2. Kunqian Yu, Cheng Luo(co-1st author), Guanrong QinㄛZijian Xu, Hong Liu, Xu Shen, Jianpeng Ma, Qinghua WangㄛCaiguang Yang, Weiliang Zhu, Hualiang Jiang. Why Tamiflu and Zanamivir works on Influenza A (H1N1)?, Cell Res. Accepted.
  3. Chao Zhang, Na Yang, Chun-hao Yang, Hua-sheng Ding, Cheng Luo, Yu Zhang, Mao-jiang Wu,Xiong-wen Zhang, Xu Shen, Hua-liang Jiang, Ling-hua Meng, Jian Ding, S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton, PLOS ONEㄛ 4(3)(2009): e4881.
  4. Cheng Luo, Peng Xie, Ronen Marmorstein. In silico screening of BRAF inhibitors, J. Med. Chem.9;51(2008), 6121-7.
  5. Yong Tang, Katrina Meeth, Eva Jiang, Cheng Luo and Ronen Marmorstein. Structure of Vps75: Implications for Histone Chaperone Function, Proc. Natl. Acad. Sci., 105 (2008), 12206-11.
  6. Hong M., Fitzgerald M.X., Harper S., Luo C., Speicher, D.W. and Marmorstein, R. Structural Basis for Dimerization in DNA Recognition by Gal4 (2008) Structure, 16(7)(2008), 1019-26.
  7. Liang Zhang, Weizhi Liu, Tiancen Hu, Li Du, Cheng Luo, Kaixian Chen, Xu Shen, and Hualiang Jiang, Structural Basis for Catalytic and Inhibitory Mechanisms of beta-Hydroxyacyl-acyl Carrier Protein Dehydratase (FabZ),J. Bio.Chem., 283, 9(2008), 5370每9.
  8. Yong-Xiang Wang, Xiang Xu, Cheng Luo, Zhang-Mei Ma, Hua-Liang Jiang, Jian-Ping Ding, Yu-Mei Wen, Mutational analysis revealed that conservation of hepatitis B virus reverse transcriptase residue 306 (rtP306) is crucial for encapsidation of pregenomic RNA, FEBS Letters 581 (2007) 558每64
  9. Hanjun Zou, Cheng Luo, Suxin Zheng, Xiaomin Luo, Weiliang Zhu, ?Kaixian Chen, Jianhua, Shen, Hualiang Jiang, Molecular insight into the interaction between IFABP and PA by using MM-PBSA and alanine scanning methods, J. Phys. Chem. B 111 (2007) 9104-13
  10. Yong-Xiang Wang, Xiang Xu, Cheng Luo, Zhang-Mei Ma, Hua-Liang Jiang, Jian-Ping Ding, and Yu-Mei Wen. A Putative New Domain Target for Anti-Hepatitis B Virus: Residues Flanking epatitis B Virus Reverse Transcriptase Residue 306 (rtP306) J. Med. Virology 9999(2007), 1-7
  11. William C. Ho, Cheng Luo, Kehao Zhao, Xiaomei Chai, M.X. Fitzgerald and Ronen Marmorstein. High-resolution structure of the p53 core domain: implications for binding small-molecule stabilizing compounds, Acta Crystallographica Section D, 62(2006) 1484-93.
  12. Lili Cheng, Jian Li, Cheng Luo, Hong Liu, Weijun Xu, Gang Chen, QiWah Liew, Weiliang Zhu, Chum Mok, Puah, Xu Shen, Hualiang, Jiang, Binding interaction of quereetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): Structure-activity relationship studies reveal salient pharmacophore features, Bioor Med Chem 14(2006) 8295-306
  13. Hongwei Jin, Suxin Zheng, Zhanli Wang, Cheng Luo, Jianghua Shen, Huajiang Jiang, Liangren Zhang, Lihe Zhang, Structural insights into the effect of isonucleosides on B-DNA duplexes using molecular-dynamics simulations, J Mol Mod 12(2006) 781-91
  14. Cheng Luo, Lingfei Xu, Suxing Zheng, Jianhua Shen, Hualiang Jiang, et al. Computational Analysis of Molecular Basis of 1:1 Interactions of NRG-1b Wild-Type and Variants with ErbB3 and ErbB4, Protein, 59 (2005) 742每56.
  15. Weiliang Zhu, Gang Chen, Lihong Hu, Xiaomin Luo, Chunshan Gui, Cheng Luo, Chum Mok Puah, Kaixian Chena and Hualiang Jianga, QSAR analyses on ginkgolides and their analogues using CoMFA, CoMSIA, and HQSAR, Bioor Med Chem Letters 13 (2005) 313每322.
  16. Weizhi Liu, Cheng Luo, Cong Han, Shuying Peng, Yiming Yang, Xu Shen and Hualiang Jiang. b-Hydroxyacyl-acyl carrier protein dehydratase (FabZ) from Helicobacter pylori: molecular cloning, stability characterization and structural modeling. Biochem Biophy Res Comm, 333 (2005) 1078每86.
  17. Cheng Luo, Haibin Luo, et al., NucleocapsidproteinofSARScoronavirustightlybindstohumanCyclophilinA, Biochem Biophy Res Comm 321 (2004) 557每65.
  18. Gang Chen, Xiaomin Luo, Weiliang Zhu, Cheng Luo, Hong Liu, Chum Mok Puah, Kaixian Chen and Hualiang Jiang, Elucidating inhibitory models of the inhibitors of epidermal growth factor receptor by docking and 3D-QSAR, Bioor Med Chem 12 (2004) 2409每17
  19. Yong Xu, Hong Liu, Chunying Niu, Cheng Luo, Xiaomin Luo, Jianhua Shen, Kaixian Chen and Hualiang Jiang, Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor, Bioor Med Chem 12 (2004) 6193每208
  20. Dong Shao, Chunyan Zou, Cheng Luo, Xican Tang and Yuanchao Li, Synthesis and evaluation of tacrine每E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer＊s disease, Bioor Med ?Chem Letters 14 (2004) 4639每42.
  21. Yu Xiao-Jing, Luo Cheng, et al. Putative hAPN receptor binding sites in SARS_CoV spike protein, Acta Pharmacol Sin; 24 (2003): 481-8
  22. Xiong Bin, Gui Chun-Shan, Xu Xiao-Ying, Luo Cheng, et al. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening, Acta Pharmacol Sin; 24 (2003): 497-504.
  23. Qin Lei, Xiong Bin, Luo Cheng, et al. Identification of probable genomic packaging signal sequence from SARS-CoV genome by bioinformatics analysis, Acta Pharmacol Sin; 24 (2003): 489-496.
  24. Cheng Luo, Wen-Ning Wang, Ming-Hua Qiao, Kang-Nian Fan, Adsorption of sulfur on NimB2 clusters: a theoretical investigation on the mechanism of strong sulfur resistance of Ni-B alloy catalyst, J Mo Cata A: Chem. 184(2002), 379每86.
  25. Luo Cheng, Shen Bai-Rong Fan Kang-Nian, TheoreticalStudyontheLocalStructureandPropertiesofElectronTransferofNi-BAmorphousAlloy, Acta Chimica Sinica: 58(2000), 948-52
 
Last Update 2009-08-24